## BSX: Boston Scientific Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.94 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (49% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($91.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results**
- Source: Finviz | 20260102T130727 | Neutral | Relevance: 100%
- Boston Scientific (NYSE: BSX) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where company executives will hold a Q&A session. Additionally, the company will webcast a conference call on February 4, 2026, to discuss its financial results for the fourth quarter and full year ended December 31, 2025. Financial news releases will precede the conference call.

**2. Boston Scientific Corp Is Quietly Winning Wall Street – But Is BSX Actually Worth Your Money?**
- Source: AD HOC NEWS | 20260103T020858 | Bullish | Relevance: 100%
- Boston Scientific Corp (BSX) is gaining traction on Wall Street, despite not being a mainstream viral sensation. The article explores whether this medical tech giant is a worthwhile investment, highlighting its robust med-tech pipeline, alignment with healthcare megatrends, and consistent stock performance. It concludes that BSX is a strong contender for long-term investors seeking stable growth in the healthcare technology sector.

**3. Boston Scientific Corp Is Quietly Winning Wall Street – But Is BSX Actually Worth Your Money?**
- Source: AD HOC NEWS | 20260102T204010 | Bullish | Relevance: 100%
- Boston Scientific Corp (BSX) is gaining traction on Wall Street, despite not being a mainstream viral sensation. The medical tech giant, known for devices in heart care and minimally invasive surgery, is seen by investors as a "grown-up stock" with steady compounding potential, riding the megatrend of an aging population needing more medical procedures. While not for short-term traders seeking quick flips, BSX is presented as a solid, long-term investment for those seeking exposure to healthcare technology.

**4. Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results**
- Source: Yahoo Finance | 20260102T130735 | Neutral | Relevance: 100%
- Boston Scientific will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, where key executives will host a Q&A session. Additionally, the company will webcast its conference call on February 4, 2026, to discuss financial results for the fourth quarter and full year 2025. Financial results will be released prior to this call, and both events will have live webcasts and replays available.

**5. Boston Scientific announces participation in the J.P. Morgan Healthcare Conference and conference call discussing fourth quarter and full year 2025 results – Company Announcement - FT.com**
- Source: Financial Times | 20260102T130131 | Neutral | Relevance: 100%
- Boston Scientific will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and will webcast a conference call on February 4, 2026, to discuss its fourth-quarter and full-year 2025 financial results and business highlights. Key executives, including Chairman and CEO Mike Mahoney, will present at both events. Financial results for 2025 will be announced on February 4 before the conference call.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $120 | $130 | -8% |
| 2025-12-17 | Canaccord Genui | $131 | $132 | -1% |
| 2025-12-17 | RBC Capital | $130 | $125 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Buy |
| 2025-12-17 | Canaccord Genui | main | Buy |
| 2025-12-17 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 3 ($1.31M) |
| Sells | 8 ($2.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 9.8% (-1.0%)
- Vanguard Group Inc: 9.3% (+0.8%)
- FMR, LLC: 6.7% (-8.2%)
- State Street Corpora: 4.4% (-0.4%)
- JPMORGAN CHASE & CO: 3.8% (+120.8%)

### Key Risks

1. Long-term trend broken: trading 6.1% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +1.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.94 indicates undervaluation relative to growth. Balance sheet: $2.6B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $140.4B |
| Beta | 0.67 |
| 52W Range | $85.98 - $109.50 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.94 |
| Forward P/E | 27.3 |
| Current P/E | 31.2 |
| YoY Growth | 14.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.6% to 0.5% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 43. Volume at 49% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.45% (CS: 46) | Neutral |
| RSI_14 | 42.8 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.939x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $94.71
- **Stop Loss:** $91.35 (3.5% risk)
- **Target:** $101.43 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 428
- **Position Value:** $40,535.88
- **Portfolio %:** 40.54%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $0.78)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.71 | $0.75 | +5.1% |
| 2025Q2 | $0.73 | $0.75 | +3.4% |
| 2025Q1 | $0.67 | $0.75 | +11.5% |
| 2024Q4 | $0.66 | $0.70 | +6.6% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*